title: High-risk nonmuscle invasive bladder cancer.
abstract: Please also verify that the expansion of HGT1 is OK as set: The risk of progression for high-grade T1 (HGT1) cancer has been recently established at 21% using updated information on large series and a meta-analysis. These outcomes are better than those classically expected supporting the rule of thirds for HGT1. The main limitation of this subgroup is that most studies are retrospective observational studies, which, compared with randomized controlled trials, are subject to various selection biases, carrying a higher risk of uncontrolled confounding factors, with potential preferential reporting of positive findings.
authors.affiliation: Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: annaorsola@gmail.com.
authors.forename: Anna
authors.initials: A
authors.lastname: Orsola
authors.affiliation: Urology Department, Fundacio Puigvert, Cartagena 340-350, Barcelona 08025, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Palou
authors.affiliation: Urology Department, Instituto Valenciano de Oncologia, Calle del Profesor Beltrán Bàguena, 8, València 46009, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Solsona
mesh_terms: D019468:Disease Management; D006801:Humans; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*
keywords: CIS; Carcinoma in situ; HGT1; High-grade T1; High-risk bladder cancer; Nonmuscle invasive bladder cancer; TUR; reTUR